Parkinson disease

2017/03/22 by Werner Poewe, Klaus Seppi, Caroline M. Tanner +6 · 4,760 citations
Medicine · Neuroscience · Psychology · #Botulinum Toxin and Related Neurological Disorders #Deep brain stimulation #Disease #Dopamine #Dopaminergic #Medicine #Neuroinflammation #Neurological disorders and treatments #Neuroscience #Parkinson's Disease Mechanisms and Treatments #Parkinson's disease #Pars compacta #Pathology #Population #Psychology #Substantia nigra

paper · doi:10.1038/nrdp.2017.13

published in Nature Reviews Disease Primers 3(1), 17013 (Springer Science and Business Media LLC)

openalex publication_date 2017/03/22 · crossref created 2017/03/22 · crossref issued 2017/03/23 · crossref published 2017/03/23 · crossref published-online 2017/03/23 · openalex created_date 2022/02/13 · crossref deposited 2022/12/22 · openalex updated_date 2026/08/09 · crossref indexed 2026/08/09

Citations

• Cell-based therapies for Parkinson disease—past insights and future potential
• AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
• Parkinson's disease: The quintessential neuropsychiatric disorder
• Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and α-Synuclein
• Staging of brain pathology related to sporadic Parkinson’s disease
• Deep Brain Stimulation for Parkinson Disease
• Pharmacological Treatment of Parkinson Disease
• Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
• MDS clinical diagnostic criteria for Parkinson's disease
• Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results
• α-Synuclein impairs macroautophagy: implications for Parkinson’s disease
• Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
• Sorting out release, uptake and processing of alpha‐synuclein during prion‐like spread of pathology
• Parkinson's disease

Cited by

• Parkinson's disease [wikipedia]